Stimwave’s drug-free wireless pain relief neurostimulator changing the lives of people suffering from chronic pain
World’s first wireless, miniature implantable device hailed by doctors and patients as a long-term therapy breakthrough.
Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, has achieved long-term success for hundreds of pain patients during the early adaptor rollout of the world’s first miniature wireless pain relief system. Embraced by pain specialists seeking non-opioid treatments, the drug-free, breakthrough remedy offers new hope to the more than 400 million people worldwide who suffer from chronic pain.
“Every day in the US an average of 120 people die as a result of drug overdose, more than from motor vehicle crashes, and another 6,700-plus are treated in emergency departments for the misuse or abuse of prescription pain medication,” said Stimwave Chairman and CEO Laura Tyler Perryman. “We believe that Stimwave’s Wireless Pain Relief technology is not only a viable option to help millions of people who suffer from chronic pain, but a potential life-saver as the US faces an epidemic of opioid addiction that in many cases is an unavoidable side effect of long-term use of addictive pain medication.”
Stimwave’s Wireless Pain Relief devices are 95% smaller than any other neuromodulation device on the market, so small, with a diameter of less than 1.5 mm, that they are simply implanted through a standard needle during an outpatient procedure and a minimally invasive receiver placement technique. Because they are wireless, with the power source discreetly worn outside the body, there is no need for the invasive “open surgery” required of earlier neuromodulation devices, reducing the risk of infection, pain at the site of a large battery, and other long-term complications of battery units and connectors that account for 85% of adverse events, according to registries. Further, this miniature wireless device is powered by a wearable antenna, easily integrated into clothing and requiring no sticky gels that could irritate the skin, and there are no “wires” protruding from the body.
"This is great news for pain specialists and chronic pain patients who previously did not have a minimally invasive implant option available for pain,” said Dr Sanjay Gupta, president of the American Pain Association and principal clinician at Atlantic Pain and Wellness Institute. “Our country is facing a horrible epidemic of drug overdose deaths. These wireless products provide an alternative to opioids, which is much needed in the armamentarium for effective pain control.”
Stimwave launched it’s FDA-cleared devices for the relief of chronic back and leg pain to a limited number of patients throughout 2015, and in March 2016 was granted FDA 510(k) for the relief of peripheral nervous system (PNS) pain, becoming the only neuromodulation device manufacturer cleared by the FDA to help reduce chronic neuropathic pain at most locations throughout the body, from back and leg pain addressed by spinal cord stimulation to PNS treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.
“The major issue with peripheral nerve stimulators in the past has always been the bulk and length of cables, connectors and pulse generators,” said Dr. Richard North, consultant and retired Professor of Neurosurgery at John Hopkins University School of Medicine. “A miniature wireless peripheral nerve stimulator will minimize the need for surgery in patients who already are suffering from pain. It has long been needed and now is finally a reality.”
Stimwave’s wireless device delivers small pulses of energy to specific nerves, triggering a reaction that enables the brain to remap pain pathways, thus providing pain relief. The Stimwave device contains no internal batteries or other toxic materials. The device is fixed in place by an anchor, so it stays “in line” with the body’s nerves, allowing a freedom of motion that is impossible with bulkier implanted devices.
The Stimwave portfolio also includes the only neuromodulation system approved for “full body” MRI examinations, meaning the device does not have to be removed for 3-Tesla MRI exams. This is a significant diagnostic breakthrough as it allows patients with pain to benefit from neuromodulation without restricting their access to MRI-assisted diagnoses, for current or future medical issues.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance